Seeking Alpha

BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying...

BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying that if the firm fails to ultimately win approval for use of the drug it could lose revenue of as much as $1B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|